Compare PubMatic Inc (PUBM) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PubMatic Inc vs 10X Genomics Inc — how do they compare? PubMatic Inc trades at $16.19 (market cap $742.01M), while 10X Genomics Inc trades at $67.59 (market cap $8.55B). The key difference: 10X Genomics Inc is far larger — about 11.5× PubMatic Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, PubMatic Inc nearer its low. Which is the better fit depends on your goals.
| PUBM | TXG | |
|---|---|---|
Market Cap | $742.01M | $8.55B |
Sector | Technology | Health |
52-Week High | $17.78 | $67.29 |
52-Week Low | $6.28 | $11.34 |
Enterprise Value | $645.14M | $8.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PubMatic (PUBM) trades at $16.29, down 1.27% on the day, with a bullish technical signal driven by moving averages and recent support above the 20-day average. The company reported Q2 2026 revenue growth of 11% year-over-year and an EPS beat, though net income margins remain negative. Positive sentiment is fueled by AI-driven ad tech adoption and strategic hires, such as the new Global Chief Revenue Officer.
Outlook: Strong analyst consensus (64.7% buy ratings) and a $20.83 price target suggest upside potential from AI product momentum and cost controls. Risks include persistent profitability challenges and CFO transition uncertainty. The stock offers growth exposure but requires monitoring of margin improvement.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
